Acceptance of emerging renal oncocytic neoplasms: a survey of urologic pathologists.
Emerging
Eosinophilic
Oncocytic
Renal neoplasms
Uropathologists
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
17 Sep 2024
17 Sep 2024
Historique:
received:
17
05
2023
accepted:
21
08
2024
revised:
20
08
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
17
9
2024
Statut:
aheadofprint
Résumé
Oncocytic renal neoplasms are a major source of diagnostic challenge in genitourinary pathology; however, they are typically nonaggressive in general, raising the question of whether distinguishing different subtypes, including emerging entities, is necessary. Emerging entities recently described include eosinophilic solid and cystic renal cell carcinoma (ESC RCC), low-grade oncocytic tumor (LOT), eosinophilic vacuolated tumor (EVT), and papillary renal neoplasm with reverse polarity (PRNRP). A survey was shared among 65 urologic pathologists using SurveyMonkey.com (Survey Monkey, Santa Clara, CA, USA). De-identified and anonymized respondent data were analyzed. Sixty-three participants completed the survey and contributed to the study. Participants were from Asia (n = 21; 35%), North America (n = 31; 52%), Europe (n = 6; 10%), and Australia (n = 2; 3%). Half encounter oncocytic renal neoplasms that are difficult to classify monthly or more frequently. Most (70%) indicated that there is enough evidence to consider ESC RCC as a distinct entity now, whereas there was less certainty for LOT (27%), EVT (29%), and PRNRP (37%). However, when combining the responses for sufficient evidence currently and likely in the future, LOT and EVT yielded > 70% and > 60% for PRNRP. Most (60%) would not render an outright diagnosis of oncocytoma on needle core biopsy. There was a dichotomy in the routine use of immunohistochemistry (IHC) in the evaluation of oncocytoma (yes = 52%; no = 48%). The most utilized IHC markers included keratin 7 and 20, KIT, AMACR, PAX8, CA9, melan A, succinate dehydrogenase (SDH)B, and fumarate hydratase (FH). Genetic techniques used included TSC1/TSC2/MTOR (67%) or TFE3 (74%) genes and pathways; however, the majority reported using these very rarely. Only 40% have encountered low-grade oncocytic renal neoplasms that are deficient for FH. Increasing experience with the spectrum of oncocytic renal neoplasms will likely yield further insights into the most appropriate work-up, classification, and clinical management for these entities.
Identifiants
pubmed: 39287823
doi: 10.1007/s00428-024-03909-2
pii: 10.1007/s00428-024-03909-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Hes O, Trpkov K (2022) Do we need an updated classification of oncocytic renal tumors? : emergence of low-grade oncocytic tumor (LOT) and eosinophilic vacuolated tumor (EVT) as novel renal entities. Mod Pathol 35(9):1140–1150
pubmed: 35273336
Amin MB, McKenney JK, Martignoni G, Campbell SC, Pal S, Tickoo SK (2022) Low grade oncocytic tumors of the kidney: a clinically relevant approach for the workup and accurate diagnosis. Mod Pathol 35(10):1306–1316
pubmed: 35896615
Samaratunga H, Egevad L, Thunders M, Iczskowski KA, van der Kwast T, Kristiansen G et al (2022) LOT and HOT … or not. The proliferation of clinically insignificant and poorly characterised types of renal neoplasia. Pathology 54(7):842–7
pubmed: 36270849
Siadat F, Trpkov K (2020) ESC, ALK, HOT and LOT: three letter acronyms of emerging renal entities knocking on the door of the WHO classification. Cancers (Basel) 12(1):168
pubmed: 31936678
Trpkov K, Williamson SR, Gill AJ, Adeniran AJ, Agaimy A, Alaghehbandan R et al (2021) Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol 34(6):1167–1184
pubmed: 33526874
Argani P, McKenney JK, Hartmann A, Hes O, Magi-Galluzzi C, Trpkov K (2022) Eosinophilic solid and cystic renal cell carcinoma: IARC [Available from: https://tumourclassification.iarc.who.int/chaptercontent/36/23
McKenney JK, Przybycin CG, Trpkov K, Magi-Galluzzi C (2018) Eosinophilic solid and cystic renal cell carcinomas have metastatic potential. Histopathology 72(6):1066–1067
pubmed: 29265482
Mehra R, Vats P, Cao X, Su F, Lee ND, Lonigro R et al (2018) Somatic Bi-allelic loss of TSC genes in eosinophilic solid and cystic renal cell carcinoma. Eur Urol 74(4):483–486
pubmed: 29941307
pmcid: 6390848
Palsgrove DN, Li Y, Pratilas CA, Lin MT, Pallavajjalla A, Gocke C et al (2018) Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum. Am J Surg Pathol 42(9):1166–1181
pubmed: 29975249
pmcid: 6089659
Parilla M, Kadri S, Patil SA, Ritterhouse L, Segal J, Henriksen KJ et al (2018) Are sporadic eosinophilic solid and cystic renal cell carcinomas characterized by somatic tuberous sclerosis gene mutations? Am J Surg Pathol 42(7):911–917
pubmed: 29668487
Trpkov K, Abou-Ouf H, Hes O, Lopez JI, Nesi G, Comperat E et al (2017) Eosinophilic solid and cystic renal cell carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity. Am J Surg Pathol 41(10):1299–1308
pubmed: 28786877
Trpkov K, Hes O, Bonert M, Lopez JI, Bonsib SM, Nesi G et al (2016) Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol 40(1):60–71
pubmed: 26414221
Williamson SR, Gadde R, Trpkov K, Hirsch MS, Srigley JR, Reuter VE et al (2017) Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. Hum Pathol 63:149–156
pubmed: 28315424
Akgul M, Al-Obaidy KI, Cheng L, Idrees MT (2021) Low-grade oncocytic tumour expands the spectrum of renal oncocytic tumours and deserves separate classification: a review of 23 cases from a single tertiary institute. J Clin Pathol 75:772
pubmed: 34168073
Guo Q, Liu N, Wang F, Guo Y, Yang B, Cao Z et al (2021) Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China. Virchows Arch 478(3):449–458
pubmed: 32918598
Kapur P, Gao M, Zhong H, Chintalapati S, Mitui M, Barnes SD et al (2021) Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney. Mod Pathol 35:333–343
pubmed: 34538873
pmcid: 9817016
Kravtsov O, Gupta S, Cheville JC, Sukov WR, Rowsey R, Herrera-Hernandez LP et al (2021) Low-grade oncocytic tumor of kidney (CK7-positive, CD117-negative): incidence in a single institutional experience with clinicopathological and molecular characteristics. Hum Pathol 114:9–18
pubmed: 33961838
Morini A, Drossart T, Timsit MO, Sibony M, Vasiliu V, Gimenez-Roqueplo AP et al (2021) Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1. Mod Pathol 35:352–360
pubmed: 34531523
Trpkov K, Williamson SR, Gao Y, Martinek P, Cheng L, Sangoi AR et al (2019) Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology 75(2):174–184
pubmed: 30895640
Williamson SR, Hes O, Trpkov K, Aggarwal A, Satapathy A, Mishra S et al (2023) Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity. Histopathology 82(2):296–304
pubmed: 36208048
Alghamdi M, Chen JF, Jungbluth A, Koutzaki S, Palmer MB, Al-Ahmadie HA et al (2024) L1 cell adhesion molecule (L1CAM) expression and molecular alterations distinguish low-grade oncocytic tumor from eosinophilic chromophobe renal cell carcinoma. Mod Pathol 37(5):100467
pubmed: 38460672
Chen YB, Mirsadraei L, Jayakumaran G, Al-Ahmadie HA, Fine SW, Gopalan A et al (2019) Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am J Surg Pathol 43(1):121–131
pubmed: 30303819
pmcid: 6686675
Farcas M, Gatalica Z, Trpkov K, Swensen J, Zhou M, Alaghehbandan R et al (2021) Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. Mod Pathol 34:2243
pubmed: 34611304
He H, Trpkov K, Martinek P, Isikci OT, Maggi-Galuzzi C, Alaghehbandan R et al (2018) “High-grade oncocytic renal tumor”: morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Arch 473(6):725–738
pubmed: 30232607
Tjota M, Chen H, Parilla M, Wanjari P, Segal J, Antic T (2020) Eosinophilic renal cell tumors with a TSC and MTOR gene mutations are morphologically and immunohistochemically heterogenous: clinicopathologic and molecular study. Am J Surg Pathol 44:943–954
pubmed: 32091432
Trpkov K, Bonert M, Gao Y, Kapoor A, He H, Yilmaz A et al (2019) High-grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex. Histopathology 75(3):440–442
pubmed: 31002177
Salles DC, Asrani K, Woo J, Vidotto T, Liu HB, Vidal I et al (2022) GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms. J Pathol 257:158–171
pubmed: 35072947
pmcid: 9310781
Li H, Argani P, Halper-Stromberg E, Lotan TL, Merino MJ, Reuter VE et al (2023) Positive GPNMB immunostaining differentiates renal cell carcinoma with fibromyomatous stroma associated with TSC1/2/MTOR alterations from others. Am J Surg Pathol 47(11):1267–1273
pubmed: 37661807
Richard PO, Jewett MA, Bhatt JR, Evans AJ, Timilsina N, Finelli A (2016) Active surveillance for renal neoplasms with oncocytic features is safe. J Urol 195(3):581–586
pubmed: 26388501
Guo J, Tretiakova MS, Troxell ML, Osunkoya AO, Fadare O, Sangoi AR et al (2014) Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am J Surg Pathol 38(11):1457–1467
pubmed: 25093518
Yang P, Cornejo KM, Sadow PM, Cheng L, Wang M, Xiao Y et al (2014) Renal cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol 38(7):895–909
pubmed: 24832166
pmcid: 4139167
Kunju LP, Wojno K, Wolf JS Jr, Cheng L, Shah RB (2008) Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum Pathol 39(1):96–101
pubmed: 17949780
Al-Obaidy KI, Eble JN, Cheng L, Williamson SR, Sakr WA, Gupta N et al (2019) Papillary renal neoplasm with reverse polarity: a morphologic, immunohistochemical, and molecular study. Am J Surg Pathol 43(8):1099–1111
pubmed: 31135486
Han G, Yu W, Chu J, Liu Y, Jiang Y, Li Y et al (2017) Oncocytic papillary renal cell carcinoma: a clinicopathological and genetic analysis and indolent clinical course in 14 cases. Pathol Res Pract 213(1):1–6
pubmed: 27931799
Lefevre M, Couturier J, Sibony M, Bazille C, Boyer K, Callard P et al (2005) Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases. Am J Surg Pathol 29(12):1576–1581
pubmed: 16327429
Nemours S, Armesto M, Arestin M, Manini C, Giustetto D, Sperga M et al (2024) Non-coding RNA and gene expression analyses of papillary renal neoplasm with reverse polarity (PRNRP) reveal distinct pathological mechanisms from other renal neoplasms. Pathology 56(4):493–503
pubmed: 38413252
Kiyozawa D, Iwasaki T, Takamatsu D, Kohashi K, Miyamoto T, Fukuchi G et al (2024) Papillary renal neoplasm with reverse polarity has low frequency of alterations in chromosomes 7, 17, and Y. Virchows Arch 485:299–306
pubmed: 38877360
Castillo VF, Trpkov K, Van der Kwast T, Rotondo F, Hamdani M, Saleeb R (2024) Papillary renal neoplasm with reverse polarity is biologically and clinically distinct from eosinophilic papillary renal cell carcinoma. Pathol Int 74(4):222–226
pubmed: 38456605
Satturwar S, Parwani AV (2023) Cytomorphology of papillary renal neoplasm with reverse polarity. Cytojournal 20:43
pubmed: 38053633
pmcid: 10695348
Nova-Camacho LM, Martin-Arruti M, Diaz IR, Panizo-Santos A (2023) Papillary renal neoplasm with reverse polarity: a clinical, pathologic, and molecular study of 8 renal tumors from a single institution. Arch Pathol Lab Med 147(6):692–700
pubmed: 36170616
Kim B, Lee S, Moon KC (2023) Papillary renal neoplasm with reverse polarity: a clinicopathologic study of 43 cases with a focus on the expression of KRAS signaling pathway downstream effectors. Hum Pathol 142:1–6
pubmed: 37797754
Yang T, Kang E, Zhang L, Zhuang J, Li Y, Jiang Y et al (2022) Papillary renal neoplasm with reverse polarity may be a novel renal cell tumor entity with low malignant potential. Diagn Pathol 17(1):66
pubmed: 36002896
pmcid: 9404576
Wei S, Kutikov A, Patchefsky AS, Flieder DB, Talarchek JN, Al-Saleem T et al (2022) Papillary renal neoplasm with reverse polarity is often cystic: report of 7 cases and review of 93 cases in the literature. Am J Surg Pathol 46(3):336–343
pubmed: 34352808
Wang T, Ding X, Huang X, Ye J, Li H, Cao S et al (2022) Papillary renal neoplasm with reverse polarity-a comparative study with CCPRCC, OPRCC, and PRCC1. Hum Pathol 129:60–70
pubmed: 35977593
Shen M, Yin X, Bai Y, Zhang H, Ru G, He X et al (2022) Papillary renal neoplasm with reverse polarity: a clinicopathological and molecular genetic characterization of 16 cases with expanding the morphologic spectrum and further support for a novel entity. Front Oncol 12:930296
pubmed: 35936734
pmcid: 9354687
Liu Y, Zhang H, Li X, Wang S, Zhang Y, Zhang X et al (2022) Papillary renal neoplasm with reverse polarity with a favorable prognosis should be separated from papillary renal cell carcinoma. Hum Pathol 127:78–85
pubmed: 35724772
Conde-Ferreiros M, Dominguez-de Dios J, Juaneda-Magdalena L, Bellas-Pereira A, San Miguel Fraile MP, PeteiroCancelo MA et al (2022) Papillary renal cell neoplasm with reverse polarity: a new subtype of renal tumour with favorable prognosis. Actas Urol Esp (Engl Ed) 46(10):600–5
pubmed: 36216763
Al-Obaidy KI, Saleeb RM, Trpkov K, Williamson SR, Sangoi AR, Nassiri M et al (2022) Recurrent KRAS mutations are early events in the development of papillary renal neoplasm with reverse polarity. Mod Pathol 35(9):1279–1286
pubmed: 35152262
Kiyozawa D, Kohashi K, Takamatsu D, Yamamoto T, Eto M, Iwasaki T et al (2021) Morphological, immunohistochemical, and genomic analyses of papillary renal neoplasm with reverse polarity. Hum Pathol 112:48–58
pubmed: 33811832
Chang HY, Hang JF, Wu CY, Lin TP, Chung HJ, Chang YH et al (2021) Clinicopathological and molecular characterisation of papillary renal neoplasm with reverse polarity and its renal papillary adenoma analogue. Histopathology 78(7):1019–1031
pubmed: 33351968
Zhou L, Xu J, Wang S, Yang X, Li C, Zhou J et al (2020) Papillary renal neoplasm with reverse polarity: a clinicopathologic study of 7 cases. Int J Surg Pathol 28(7):728–734
pubmed: 32403965
Kim SS, Cho YM, Kim GH, Kee KH, Kim HS, Kim KM et al (2020) Recurrent KRAS mutations identified in papillary renal neoplasm with reverse polarity-a comparative study with papillary renal cell carcinoma. Mod Pathol 33(4):690–699
pubmed: 31953522
Al-Obaidy KI, Eble JN, Nassiri M, Cheng L, Eldomery MK, Williamson SR et al (2020) Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. Mod Pathol 33(6):1157–1164
pubmed: 31534204
Al-Obaidy KI, Eble JN, Nassiri M, Cheng L, Eldomery MK, Williamson SR et al (2019) Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. Mod Pathol 33:1157–1164
pubmed: 31534204
Pivovarcikova K, Grossmann P, Hajkova V, Alaghehbandan R, Pitra T, Perez Montiel D et al (2021) Renal cell carcinomas with tubulopapillary architecture and oncocytic cells: molecular analysis of 39 difficult tumors to classify. Ann Diagn Pathol 52:151734
pubmed: 33838490